Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Curr Med Chem. 2021;28(11):2114-2136. doi: 10.2174/0929867327999200817104912.
The costs of developing, validating and buying new drugs are dramatically increasing. On the other hand, sobering economies have difficulties in sustaining their healthcare systems, particularly in countries with an elderly population requiring increasing welfare. This conundrum requires immediate action, and a possible option is to study the large, already present arsenal of drugs approved and to use them for innovative therapies. This possibility is particularly interesting in oncology, where the complexity of the cancer genome dictates in most patients a multistep therapeutic approach. In this review, we discuss a) Computational approaches; b) preclinical models; c) currently ongoing or already published clinical trials in the drug repurposing field in oncology; and d) drug repurposing to overcome resistance to previous therapies.
开发、验证和购买新药的成本正在大幅上升。另一方面,经济形势严峻,难以维持其医疗保健系统,尤其是在人口老龄化、需要增加福利的国家。这个难题需要立即采取行动,一个可能的选择是研究大量已经批准的药物,将其用于创新疗法。在肿瘤学中,这种可能性尤其有趣,因为癌症基因组的复杂性决定了大多数患者需要采用多步骤的治疗方法。在这篇综述中,我们讨论了 a)计算方法;b)临床前模型;c)肿瘤学药物再利用领域目前正在进行或已经发表的临床试验;d)药物再利用以克服对先前治疗的耐药性。